Back to discover

Protein / target

Interleukin-13

Encoded byIL13P35225Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
2
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
High-Quality Pocket

Protein at a glance

Biological role

Interleukin-13 receptor binding

Strongest disease association

Asthma

Via encoding gene IL13 · Genetic evidence · score 0.95

Therapeutic position

Established drug target

Antibodies

Research activity

Emerging research

7 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Cytokine that plays important roles in allergic inflammation and immune response to parasite infection.

View complete UniProt function annotation

Cytokine that plays important roles in allergic inflammation and immune response to parasite infection (PubMed:8096327, PubMed:8097324). Synergizes with IL2 in regulating interferon-gamma synthesis (PubMed:8096327). Stimulates B-cell proliferation, and activation of eosinophils, basophils, and mast cells (PubMed:7903680, PubMed:8759755). Plays an important role in controlling IL33 activity by modulating the production of transmembrane and soluble forms of interleukin-1 receptor-like 1/IL1RL1 (By similarity). Displays the capacity to antagonize Th1-driven proinflammatory immune response and downregulates synthesis of many proinflammatory cytokines including IL1, IL6, IL10, IL12 and TNF through a mechanism that partially involves suppression of NF-kappa-B (By similarity). Also functions on nonhematopoietic cells, including endothelial cells where it induces vascular cell adhesion protein 1/VCAM1, which is important in the recruitment of eosinophils (PubMed:8639787). Exerts its biological effects through its receptors which comprises the IL4R chain and the IL13RA1 chain, to activate JAK1 and TYK2, leading to the activation of STAT6 (PubMed:9013879). Aside from IL13RA1, another receptor IL13RA2 acts as a high affinity decoy for IL13 and mediates internalization and depletion of extracellular IL13 (PubMed:21622864). Induces inflammatory response in esophageal epithelium which results in a dysregulation of desmosome intercellular adhesion junctions, via down-regulation of DSG1 (PubMed:24220297)

Subcellular location

Secreted
Domains and Gene Ontology detail (41)

Gene Ontology

  • Ccytoplasm
  • Cexternal side of plasma membrane
  • Cextracellular region
  • Cextracellular space
  • Cplasma membrane
  • Fcytokine activity
  • Finterleukin-13 receptor binding
  • Papoptotic process
  • Pcell surface receptor signaling pathway via JAK-STAT
  • Pcellular response to mechanical stimulus
  • PERK1 and ERK2 cascade
  • Pimmune response

146 aa · 16 kDa

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Immune signallingUniProt · GO · ReactomeTranscriptional regulationGOApoptosis & cell deathGO
View supporting evidence

Immune signalling

  • ·Cytokine that plays important roles in allergic inflammation and immune response to para…
  • ·cytokine activity
  • ·interleukin-13 receptor binding
  • ·immune response

Transcriptional regulation

  • ·positive regulation of gene expression
  • ·positive regulation of transcription by RNA polymerase II

Apoptosis & cell death

  • ·apoptotic process
  • ·negative regulation of endothelial cell apoptotic process
View underlying pathways (3)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

IL13RA1IL4RIL13RA2IL4IL5STAT6IFNGTNFIL6IL1BIL13

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Approved medicines with mapped indications

2 medicines · 2 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Dermatitis, Atopic2 medicines
Eczema2 medicines

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

2

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

tralokinumab
Narrow target profileApprovedInhibitor

Interleukin-13 inhibitor

Indicated for Dermatitis, Atopic, Eczema

Direct interaction with this protein · Only this protein recorded as a target

lebrikizumab
Narrow target profileApprovedInhibitor

Interleukin-13 inhibitor

Indicated for Dermatitis, Atopic, Eczema

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene IL13

Gene-level evidence surfaced through the gene IL13that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Asthma
0.98Well supported

Genetic evidence dominant · Open Targets 0.70

Dermatitis, Atopic
0.97Well supported

Genetic evidence dominant · Open Targets 0.73

Psoriasis
0.87Well supported

Genetic evidence dominant · Open Targets 0.54

Respiratory Tract Diseases
0.83Well supported

Genetic evidence dominant · Open Targets 0.51

Rhinitis, Allergic
0.82Well supported

Genetic evidence dominant · Open Targets 0.54

View evidence synthesis (5)
AsthmaWell supported
0.98
agreement 0.891.00
Genetic55%Clinical29%Literature9%Animal model7%RNA expression1%

Open Targets aggregate 0.70 · 5 independent evidence families

Dermatitis, AtopicWell supported
0.97
agreement 0.861.00
Genetic52%Clinical44%Literature4%

Open Targets aggregate 0.73 · 3 independent evidence families

PsoriasisWell supported
0.87
agreement 0.760.97
Genetic92%Literature7%Clinical1%

Open Targets aggregate 0.54 · 3 independent evidence families

Respiratory Tract DiseasesWell supported
0.83
agreement 0.690.97
Genetic98%Literature2%

Open Targets aggregate 0.51 · 2 independent evidence families

Rhinitis, AllergicWell supported
0.82
agreement 0.710.93
Genetic84%Clinical10%Literature6%Genetic literaturedup

Open Targets aggregate 0.54 · 3 independent evidence families · 1 not counted as duplicate

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Dermatitis, Atopic0.73
Asthma0.70
Rhinitis, Allergic0.54
Psoriasis0.54
Respiratory Tract Diseases0.51
Skin Diseases0.49
Childhood onset asthma0.49
Hypersensitivity0.47

Drug development

7 compounds recorded · 2 approved · 5 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 2 drugs that target this protein in Forefront's canonical graph (2 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (7)
LEBRIKIZUMABApproval
ANRUKINZUMABPhase 2
CNTO-5825Phase 1
QAX-576Phase 2
ROMILKIMABPhase 2
CENDAKIMABPhase 3
TRALOKINUMABApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesEmerging

Feasibility evidence (high-quality pocket) — no clinical-stage drug of this modality recorded.

AntibodiesStrong

Approved Drug and GO CC high conf support this modality.

View underlying tractability evidence (5)
SM · High-Quality PocketAB · Approved DrugAB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMM

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

drug toxicityClinPGx

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

ClinicalTrials.gov via the drug-target graph.

What's happening now

6

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 2 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Regulatory approval2023-11-16

    Approval: Ebglyss (EMA)

    ema · regulatory · ema · via lebrikizumab

  2. New publication2023-06-01
    Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial.

    JAMA dermatology · 2023 · 112 citations · Europe PMC · via tralokinumab

  3. Regulatory approval2021-06-17

    Approval: Adtralza (EMA)

    ema · regulatory · ema · via tralokinumab

  4. New publication2020-12-30
    Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).

    The British journal of dermatology · 2021 · 430 citations · Europe PMC · via tralokinumab

  5. New publication2020-04-01
    Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.

    JAMA dermatology · 2020 · 242 citations · Europe PMC · via lebrikizumab

  6. New publication2014-10-10
    Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study.

    Gut · 2015 · 126 citations · Europe PMC · via tralokinumab

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.

Research activity

7 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.